Frequently Asked Questions

What is the primary objective of a pharmacology study for an siRNA-LNP therapeutic?

The main objective is to establish a clear relationship between the administered amount of the siRNA-LNP construct and the magnitude of the biological effect, typically target gene knockdown. This data informs the selection of an appropriate range for subsequent IND-enabling toxicology studies.

How does LNP formulation impact the design of these studies?

The composition of the lipid nanoparticle (ionizable lipids, helper lipids, cholesterol, PEG-lipids) directly influences biodistribution, cellular uptake, and potential for off-target effects. The study design must account for the unique pharmacokinetic and pharmacodynamic (PK/PD) profile of the specific LNP formulation.

Which endpoints are typically measured to assess efficacy?

Key efficacy endpoints include quantifying the reduction of target mRNA and protein levels in relevant tissues. Bioanalytical assays are developed and qualified in a phase-appropriate manner to ensure precision. These efficacy readouts are correlated with safety markers to define the therapeutic window.

Additional Insights

Defining the response curve for advanced therapeutics and complex biologics, such as siRNA payloads delivered via lipid nanoparticles, is a multi-faceted challenge. Applying proven intelligence in preclinical pharmacology is necessary to generate a data package that withstands regulatory scrutiny. A standard template does not exist; each program requires a data-driven strategy tailored to the asset’s specific modality and target indication.

The design of these pharmacology assessments must consider variables that extend beyond the siRNA payload itself. Research into scalable LNP production methods indicates that manufacturing consistency directly correlates to biological delivery and potency (PMID: 34189917). This link between production and performance underscores the need for pharmacology studies that can accurately characterize the biological activity of a specific, well-defined test article.

Key components of a robust LNP-siRNA pharmacology study include:

• Exposure-Range Finding: Execution of a multi-arm study to identify the minimal effective exposure level and the maximum tolerated level, establishing a preliminary therapeutic index.
• PK/PD Correlation: Time-course analysis to map the concentration of the therapeutic in circulation and target tissues with the onset, magnitude, and duration of target gene silencing.
• Endpoint Selection: Utilization of qualified bioanalytical methods to measure target mRNA knockdown, protein reduction, and relevant biomarkers.
• System Selection: Careful selection of an appropriate biological system, particularly for therapeutics where complex immune system interactions are anticipated.

This rigorous approach to pharmacology and efficacy evaluation forms the foundation of the preclinical data package. The scientific leadership team, which now forms the core of Franklin Biolabs, brings a track record that includes a 100% successful IND submission rate since 2019. This historical performance, achieved prior to our 2024 launch, informs our strategy to move candidates toward regulatory filing in 18-24 months.

Return to Preclinical | Translational Services Hub